drugset / Trial / NCT00787111

Extended Management and Measurement of Autism

NCT00787111

Phase 3 Terminated 128 enrolled Neuropharm Autism Speaks · collab
NaSingle-groupOpen-labelTreatment

Summary

This open-label research study will continue to monitor the safety of fluoxetine in children after their completion of a previous double-blind placebo controlled clinical study, with fluoxetine. The study will also look at the effect of fluoxetine on IQ (Intelligence Quotient) over an 18 month period.

Timeline

Start
2008-11
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 2 mg Oral
Subject Fluoxetine Small molecule 4 mg Oral
Subject Fluoxetine Small molecule 54 mg Oral

Indications